HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.

Abstract
This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P = 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P = 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P = 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization.
AuthorsDavid Jiménez Castro, Gema Díaz, David Martí, Carlos Escobar, Javier Ortega, Sergio García-Rull, Joaquin Picher, Antonio Sueiro
JournalBlood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood Coagul Fibrinolysis) Vol. 18 Issue 2 Pg. 173-7 (Mar 2007) ISSN: 0957-5235 [Print] England
PMID17287635 (Publication Type: Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Enoxaparin
  • Acenocoumarol
Topics
  • Acenocoumarol (administration & dosage, toxicity)
  • Aged
  • Aged, 80 and over
  • Enoxaparin (administration & dosage, toxicity)
  • Female
  • Hemorrhage (chemically induced)
  • Humans
  • In Vitro Techniques
  • Length of Stay
  • Middle Aged
  • Pulmonary Embolism (drug therapy)
  • Secondary Prevention
  • Venous Thrombosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: